                         SEQUENCE LISTING

<110>  Revance Therapeutics, Inc.
       Ho, Connie
       Du, Alice
       Browne, Dan
 
<120>  METHODS AND COMPOSITIONS FOR TREATING SKIN CONDITIONS ASSOCIATED 
       WITH VASCULAR HYPER-REACTIVITY

<130>  REVA-003/01WO

<150>  US 61/165,701
<151>  2009-04-01

<160>  8     

<170>  PatentIn version 3.5

<210>  1
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  reverse HIV-TAT

<400>  1

Arg Arg Arg Gln Arg Arg Lys Lys Arg 
1               5                   


<210>  2
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HIV-TAT

<400>  2

Arg Lys Lys Arg Arg Gln Arg Arg Arg 
1               5                   


<210>  3
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  translocation peptide


<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Xaa may be Lys present in 5 to 20 copies

<400>  3

Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Xaa Gly Arg Lys Lys Arg 
1               5                   10                  15      


Arg Gln Arg Arg Arg 
            20      


<210>  4
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  translocation peptide


<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Xaa may be Lys present in 5 to 20 copies

<400>  4

Arg Arg Arg Gln Arg Arg Lys Lys Arg Gly Xaa Gly Arg Arg Arg Gln 
1               5                   10                  15      


Arg Arg Lys Lys Arg 
            20      


<210>  5
<211>  35
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  translocation peptide

<400>  5

Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Lys Lys Lys Lys Lys Lys 
1               5                   10                  15      


Lys Lys Lys Lys Lys Lys Lys Lys Lys Gly Arg Lys Lys Arg Arg Gln 
            20                  25                  30          


Arg Arg Arg 
        35  


<210>  6
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HIV-TAT peptide fragment


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa may be absent or may be Gly present in 1 to 20 copies

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  Xaa may be absent or may be Gly present in 1 to 20 copies

<400>  6

Xaa Arg Gly Arg Asp Asp Arg Arg Gln Arg Arg Arg Xaa 
1               5                   10              


<210>  7
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HIV-TAT peptide fragment


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa may be absent or may be Gly present in 1 to 20 copies

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  Xaa may be absent or may be Gly present in 1 to 20 copies

<400>  7

Xaa Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Xaa 
1               5                   10              


<210>  8
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HIV-TAT peptide fragment


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa may be absent or may be Gly present in 1 to 20 copies

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Xaa may be absent or may be Gly present in 1 to 20 copies

<400>  8

Xaa Arg Lys Lys Arg Arg Gln Arg Arg Arg Xaa 
1               5                   10      


